Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Oragenics Inc. (OGEN:NYSE), powered by AI.
Oragenics Inc. is currently trading at $0.61. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Oragenics Inc. on Alpha Lenz.
Oragenics Inc.'s P/E ratio is -0.1.
“Oragenics Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -243.9%.”
Ask for details →Oragenics Inc. is a biotechnology company that focuses on the development and commercialization of pharmaceutical products for oral health and infectious diseases. The company is engaged in the creation of novel therapies utilizing its proprietary biological platform technologies. A key area of its research is aimed at the development of antibiotics to combat resistant strains of bacteria, often addressing public health challenges that require innovative solutions. Oragenics primarily targets sectors that include pharmaceuticals, healthcare, and biotherapeutics, impacting both consumer and clinical markets. The company is headquartered in Tampa, Florida, and continues to play a significant role in pioneering research within its niche, contributing to advancements in medical science and therapeutic options. By leveraging cutting-edge research in microbiomics, Oragenics is not only integral to addressing significant health concerns but also a notable contributor to the broader biotechnology and pharmaceutical industries.
“Oragenics Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -243.9%.”
Ask for details →Oragenics Inc. (ticker: OGEN) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 3 employees. Market cap is $1M.
The current price is $0.611 with a P/E ratio of -0.13x and P/B of 0.16x.
ROE is -243.94%.